Published in J Hepatol on January 01, 1985
Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother (1993) 1.78
Long-term experience on surgical treatment of alveolar echinococcosis. Langenbecks Arch Surg (2008) 1.01
Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos. Ann Surg (1995) 0.95
In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother (1998) 0.91
In vitro effects of flubendazole on Echinococcus granulosus protoscoleces. Parasitol Res (2005) 0.90
Comparison of albendazole, mebendazole and praziquantel chemotherapy of Echinococcus multilocularis in a gerbil model. Gut (1989) 0.88
In vitro and in vivo effects of flubendazole on Echinococcus granulosus metacestodes. Parasitol Res (2006) 0.85
Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet (1966) 2.65
Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther (1985) 2.50
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results. Eur J Clin Pharmacol (1980) 1.73
Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol (1989) 1.72
Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology (1988) 1.53
Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol (1988) 1.48
Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: a retrospective feasibility study. Hepatology (1997) 1.43
Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat. J Pharmacol Exp Ther (1976) 1.41
Interventional musculoskeletal ultrasonography: Precautions and contraindications. J Ultrasound (2010) 1.39
Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther (1976) 1.35
Lactulose in the treatment of portal-systemic encephalopathy. Report of a symposium. Gastroenterology (1970) 1.26
Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol (1983) 1.13
Rate of drug metabolism in man measured by 14CO2-breath analysis. Eur J Clin Pharmacol (1978) 1.08
Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology (1990) 1.02
Effect of plasma mebendazole concentrations in the treatment of human echinococcosis. Am J Trop Med Hyg (1985) 1.01
[Bacterial endocarditis due to an actinobacillus]. Dtsch Med Wochenschr (1967) 1.01
Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol (1986) 0.96
Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature. Am J Med (1971) 0.96
Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur J Clin Pharmacol (1987) 0.95
Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man. Eur J Clin Pharmacol (1981) 0.95
Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur J Clin Pharmacol (1981) 0.94
Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations. Eur J Clin Pharmacol (1992) 0.93
The 30-minute aminopyrine breath test: optimization of sampling times after intravenous administration of 14C-aminopyrine. Digestion (1988) 0.93
Hepatic functional deterioration after portacaval shunt in the rat. Effects on sulfobromophthalein transport-maximum, indocyanine green clearance and galactose elimination capacity. Gastroenterology (1976) 0.93
[Positive diagnosis of Gilbert syndrome. Retrospective analysis of 59 cases with special reference to the nicotinic acid test]. Schweiz Med Wochenschr (1982) 0.92
Dose dependence of the 14C-aminopyrine breath test. Intrasubject comparison of tracer and pharmacological doses. Eur J Clin Pharmacol (1977) 0.92
Penetration of ciprofloxacin into the cerebrospinal fluid of patients with uninflamed meninges. J Antimicrob Chemother (1990) 0.92
The lower-extremity musculature in chronic symptomatic instability of the anterior cruciate ligament. J Bone Joint Surg Am (1985) 0.89
Amiodarone-induced vasculitis and polyserositis. Postgrad Med J (1985) 0.89
Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis (1983) 0.89
Measurement of liver volume by ultrasound and computed tomography. J Clin Ultrasound (1983) 0.89
Quality of life and patterns of recurrence following transhiatal esophagectomy for cancer: results of a prospective follow-up in 50 patients. World J Surg (1988) 0.88
Assessment of the hepatic circulation in humans: new concepts based on evidence derived from a D-sorbitol clearance method. J Lab Clin Med (1998) 0.87
Comparison of serine and hippurate as precursor equivalents during infusion of [15N]glycine for measurement of fractional synthetic rates of apolipoprotein B of very-low-density lipoprotein. Metabolism (1995) 0.87
A new look at the plasma disappearance of sulfobromophthalein (BSP): correlation with the BSP transport maximum and the hepatic plasma flow in man. J Lab Clin Med (1976) 0.87
Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients. Hepatogastroenterology (1982) 0.86
Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology (1987) 0.85
Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet (1987) 0.85
[1st use of lactitol in the treatment of porto-systemic encephalopathy]. Schweiz Med Wochenschr (1982) 0.84
Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr (1986) 0.84
Criteria for assessment of functional impairment in patients with cirrhosis of the liver. Eur J Clin Invest (1973) 0.84
Fortuitous discovery of urate nephrolithiasis in rats subjected to portacaval anastomosis. Experientia (1972) 0.84
The mechanism of action of lactulose in portal-systemic encephalopathy. Non-ionic diffusion of ammonia in the canine colon. Rev Eur Etud Clin Biol (1971) 0.84
Principles of Wheeler's method for the quantification of hepatic excretory function. Helv Med Acta (1973) 0.83
[Treatment of chronic porto-systemic encephalopathy with lactulose]. Schweiz Med Wochenschr (1969) 0.83
The Eck fistula rat: definition of an experimental model. Eur J Clin Invest (1972) 0.83
Students as tutors in problem-based learning: does it work? Med Educ (1992) 0.83
Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest (1987) 0.83
Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol (1983) 0.82
Polymorphic acetylation and aminopyrine demethylation in Gilbert's syndrome. Eur J Clin Invest (1978) 0.82
The excretory capacity of the isolated rat liver. An in vitor--in vivo comparison. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.82
[What does the BSP retention measure? Comparison of BSP-transport maximum, storage capacity and capacity for elimination of galactose]. Schweiz Med Wochenschr (1973) 0.82
Defective renal handling of water in the rat with a portacaval shunt. Eur J Clin Invest (1976) 0.81
New aspects in the management of alveolar echinococcosis involving the liver. World J Surg (1986) 0.81
Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery. Br J Anaesth (1990) 0.81
The portacaval and splenocaval shunt in the normal rat. A morphometric and functional reevaluation. J Hepatol (1985) 0.81
Syndrome of intestinal arterial insufficiency ("abdominal angina"). Arch Intern Med (1966) 0.80
Assessment of prognosis in advanced liver disease: to score or to measure, that's the question. Hepatology (1986) 0.80
Paracetamol test: modification by renal function, urine flow and pH. Eur J Clin Pharmacol (1990) 0.80
Wrong idea, good results (the lactulose story). N Engl J Med (1969) 0.80
Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. Eur J Clin Pharmacol (1985) 0.80
[Encephalopathy of the rat with portacaval shunt: an animal model for therapeutic experiments]. Schweiz Med Wochenschr (1971) 0.80
Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver. Hepatology (1983) 0.80
Physiologic and pathophysiologic aspects of the hepatic hemodynamics. Prog Liver Dis (1972) 0.79
Dose equivalence of midazolam and triazolam. A psychometric study based on flicker sensitivity, reaction time and digit symbol substitution test. Eur J Clin Pharmacol (1989) 0.79
[Galactose elimination capacity, a reliable test for quantitative comprehension of the liver function]. Schweiz Med Wochenschr (1971) 0.79
Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis. Eur J Clin Pharmacol (1983) 0.79
Increased responsiveness of gastric mucosa to gastrin stimulation in the Eck fistula rat. Gastroenterology (1974) 0.79
The defect of uric acid metabolism in Eck-fistula rats. J Lab Clin Med (1977) 0.79
Effect of pentoxifylline on liver plasma flow in normal man. Eur J Clin Pharmacol (1991) 0.79
[Treatment of inguinal hernias by classical approach and under local anesthesia]. Ann Chir (1996) 0.78
Phenytoin therapy for epileptic children: evaluation of salivary and plasma concentrations and of methods of assessing compliance. Dev Med Child Neurol (1981) 0.78
The fate of the ethanol analogue 1,3-butanediol in the dog. An in vivo-in vitro comparison. Biochem Pharmacol (1981) 0.78
Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III. J Hepatol (1990) 0.78
Pylorus-preserving pancreatoduodenectomy. Experience in 20 patients. HPB Surg (1991) 0.78
[Mebendazole therapy in echinococcosis. Long-term study and course parameters in 8 patients]. Dtsch Med Wochenschr (1984) 0.78
Preferential reduction of first-pass elimination by ethanol. Model experiments with clomethiazole in the rabbit. J Pharmacol Exp Ther (1981) 0.78
Treatment of patients with benign recurrent intrahepatic cholestasis. Hepatology (1989) 0.78
Higher levels of serum aminoterminal type III procollagen peptide, and laminin in alcoholic than in nonalcoholic cirrhosis of equal severity. J Hepatol (1992) 0.78
[Treatment of chronic hepatic coma with lactulose]. Ther Umsch (1969) 0.78
Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens. Eur J Clin Pharmacol (1985) 0.77
Prognosis in synchronous colorectal carcinomas. Z Gastroenterol (1988) 0.77
Hepatic metabolism of aminopyrine in patients with chronic renal failure. Clin Sci Mol Med (1978) 0.77
Excessive motor impairment two hours after triazolam in the elderly. Eur J Clin Pharmacol (1990) 0.77
Hepatic arteriography in cirrhosis of the liver and portal hypertension. Correlation between angiographic and functional data. Invest Radiol (1973) 0.77
Bile formation in the intact pig. Am J Vet Res (1974) 0.77
The rat with portacaval shunt: an animal model with chronic hepatic failure. Pharmacol Ther B (1979) 0.77
Acquisition of an embryonal biochemical feature in the rat liver after portacaval shunt. Experientia (1973) 0.76
Stereoselectivity of differential routes of drug metabolism: the fate of the enantiomers of [14C]mephenytoin in the dog. J Pharmacol Exp Ther (1979) 0.76
The influence of gestational age on bilirubin conjugation in newborns. Eur J Clin Invest (1991) 0.76
Arbutin absorption in human small intestine: a simple procedure for the determination of active sugar uptake in peroral biopsy specimens. Clin Chim Acta (1969) 0.76
A rabbit model allowing access to portal vein, vena cava, aorta and duodenum without anesthesia. Arzneimittelforschung (1981) 0.75
Increased systemic availability of drugs during acute ethanol intoxication: studies with mephenytoin in the dog. J Pharmacol Exp Ther (1980) 0.75
The influence of prednisolone on hepatic function in normal subjects. Effects on galactose elimination capacity, sulfobromophthalein transport maximum and storage capacity, and D-glucaric acid output. Am J Dig Dis (1977) 0.75
Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis. Eur J Clin Pharmacol (1986) 0.75
Triazolam concentration-effect relationships in healthy subjects. Clin Pharmacol Ther (1983) 0.75
A practical approach to quantitate hepatic excretory function. Yale J Biol Med (1974) 0.75